Boosting vaccinations with peptide-pulsed CD34+ progenitor-derived dendritic cells can expand long-lived melanoma peptide-specific CD8+ T cells in patients with metastatic melanoma Journal Article
| Authors: | Palucka, A. K.; Dhodapkar, M. V.; Paczesny, S.; Ueno, H.; Fay, J.; Banchereau, J. |
| Article Title: | Boosting vaccinations with peptide-pulsed CD34+ progenitor-derived dendritic cells can expand long-lived melanoma peptide-specific CD8+ T cells in patients with metastatic melanoma |
| Abstract: | The immunogenicity of dendritic cell (DC)-based vaccines has been shown in patients with advanced cancer, but it has not yet been established whether the elicited cancer-specific immunity is durable and whether it can be maintained by boosting vaccinations. The authors showed earlier, in 18 HLA-A*0201 metastatic melanoma patients, that four vaccinations over 6 weeks with peptide-loaded CD34-DCs (the induction phase) expand in the blood melanoma-specific CD8+ T cells, as documented by melanoma peptide-specific IFN-γ ELISPOT and cytotoxic T-lymphocyte (CTL) activity against melanoma cell lines. The authors show here that the melanoma peptide-specific CD8+ T-cell immunity is short-lived, but it could be reactivated in 7 of 11 patients who received four boosting vaccinations with peptide-loaded CD34-DCs. Expansion of recall memory CD8+ T cells was confirmed by tetramer binding and CTL activity against melanoma peptide-pulsed T2 cells. In two patients boosted over 15 months, induced melanoma peptide-specific recall memory CD8+ T cells lasted at least 6 months. Thus, boosting vaccination with peptide-loaded CD34-DCs can expand long-lived tumor peptide-specific immunity. Copyright © 2005 by Lippincott Williams & Wilkins. |
| Keywords: | clinical article; advanced cancer; cd8 antigen; t lymphocyte; cd8-positive t-lymphocytes; cd34 antigen; dendritic cell vaccine; melanoma; metastasis; cell line; cytotoxicity; peptide; time factors; stem cell; cytokines; dendritic cells; immune response; leukocytes, mononuclear; gamma interferon; cancer vaccines; immunogenicity; vaccination; cytotoxic t lymphocyte; neoplasm metastasis; peptides; tumor immunity; enzyme-linked immunosorbent assay; enzyme linked immunospot assay; antigens, cd34; interferon type ii; tumor vaccines; cd8+t-cell immunity |
| Journal Title: | Journal of Immunotherapy |
| Volume: | 28 |
| Issue: | 2 |
| ISSN: | 1524-9557 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2005-03-01 |
| Start Page: | 158 |
| End Page: | 168 |
| Language: | English |
| PUBMED: | 15725960 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 26" - "Export Date: 24 October 2012" - "CODEN: JOIME" - "Source: Scopus" |
